Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a report issued on Thursday,Benzinga reports. They presently have a $5.00 price target on the stock. D. Boral Capital’s price objective suggests a potential upside of 320.17% from the stock’s previous close.

Separately, Wall Street Zen downgraded Hoth Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 21st. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Hoth Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $4.00.

Hoth Therapeutics Stock Performance

Shares of HOTH stock opened at $1.19 on Thursday. The business’s fifty day moving average is $1.00 and its 200-day moving average is $1.05. The stock has a market cap of $15.72 million, a PE ratio of -1.04 and a beta of 0.55. Hoth Therapeutics has a 1 year low of $0.58 and a 1 year high of $3.80.

Hoth Therapeutics (NASDAQ:HOTH) last released its earnings results on Monday, May 12th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.07. Equities research analysts predict that Hoth Therapeutics will post -1.36 earnings per share for the current year.

Institutional Investors Weigh In On Hoth Therapeutics

An institutional investor recently raised its position in Hoth Therapeutics stock. Geode Capital Management LLC lifted its stake in Hoth Therapeutics, Inc. (NASDAQ:HOTH) by 15.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 95,946 shares of the company’s stock after acquiring an additional 13,038 shares during the period. Geode Capital Management LLC owned approximately 1.39% of Hoth Therapeutics worth $72,000 at the end of the most recent reporting period. 7.08% of the stock is owned by hedge funds and other institutional investors.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.